Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 13/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 12/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 12/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.56 |
| ▸ | HTR1D | P28221 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HRH2 | P25021 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Romifidine SCHEMBL29761110 | 1.00 | ADRA2C (0.56) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Romifidine SCHEMBL1970327 | 0.98 | ADRA2C (0.57) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Romifidine SCHEMBL22616284 | 0.98 | ADRA2C (0.55) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Romifidine SCHEMBL22616255 | 0.92 | ADRA2C (0.49) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Romifidine SCHEMBL22616210 | 0.92 | ADRA2C (0.49) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Romifidine SCHEMBL22616229 | 0.91 | ADRA2C (0.48) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Romifidine SCHEMBL22616310 | 0.90 | HTR1D (0.50) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| SCHEMBL11182818 | 0.89 | ADRA2C (0.65) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| SCHEMBL9920134 | 0.89 | ADRA2C (0.65) | ADRA2CADRA2AADRA2BADRA1AADRA1D | |
| Romifidine SCHEMBL22616282 | 0.89 | ADRA2A (0.46) | ADRA2CADRA2AADRA2BADRA1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 710 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-12501899-B2 | Mite infestation treatment | VETO-PHARMA (FR) | 2025-12-23 | — | — | US | claimed |
| EP-4661680-A1 | COMPOSITION FOR CONTROLLING MITE INFESTATION | Veto-Pharma (FR) | 2025-12-17 | — | — | EP | claimed |
| WO-2025080559-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | claimed |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2025-04-10 | — | — | US | claimed |
| WO-2024226608-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | AGLAEAPHARMA INC. (US) | 2024-10-31 | — | — | WO | claimed |
| WO-2024165712-A1 | COMPOSITION FOR CONTROLLING MITE INFESTATION | VETO-PHARMA (FR) | 2024-08-15 | — | — | WO | claimed |
| EP-4413861-A1 | COMPOSITION FOR CONTROLLING MITE INFESTATION | Veto-Pharma (FR) | 2024-08-14 | — | — | EP | claimed |
| US-20240139181-A1 | METHODS FOR INDUCING PUPIL DILATION | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2024-05-02 | — | — | US | claimed |
| US-20230404979-A1 | ALPHA-2 ADRENERGIC RECEPTOR AGONISTS TO REDUCE MORTALITY AND IMPROVE OUTCOMES IN VIRAL RESPIRATORY SYNDROMES | RUSH UNIVERSITY MEDICAL CENTER (US) | 2023-12-21 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| EP-0719139-A1 | USE OF CENTRALLY ACTIVE ALPHAAGONISTS FOR INHIBING POSTRAUMATIC METABOLIC STRESS | Dr. Karl Thomae GmbH (DE) | 1996-07-03 | — | — | EP | claimed |
| WO-1995003798-A2 | USE OF CENTRALLY EFFECTIVE α-2 AGONISTS FOR INHIBITING POSTAGGRESSION METABOLISM | BOEHRINGER INGELHEIM INT (DE) | 1995-02-09 | — | — | WO | claimed |
| EP-0170193-B1 | FEEDSTUFF ADDITIVE FOR THE GROWTH PROMOTING OF AGRICULTURAL USEFUL ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1991-12-27 | — | — | EP | claimed |
| US-4853402-A | 2-SUBSTITUTED-2-IMIDAZOLINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1989-08-01 | — | — | US | claimed |
| EP-0170193-A2 | Feedstuff additive for the growth promoting of agricultural useful animals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-02-05 | — | — | EP | claimed |
| EP-0031429-B1 | 2-(N-(2-FLUORO-6-BROMOPHENYL)-N-(THIEMYL-2-METHYL)-AMINO)-2-IMIDAZOLINE, ITS ADDITION SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | C.H. BOEHRINGER SOHN (DE) | 1984-07-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12501899-B2 | Mite infestation treatment | RHOA, NPEPPS, TUBA3E | ADRA2C 2479/4885ADRA2A 3402/4885ADRA2B 3269/4885 |
| US-20250114370-A1 | METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE | ADRA2A, ADRA2C, OPRM1 | ADRA2C 2/4885ADRA2A 1/4885ADRA2B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.